QCOR Questcor Pharmaceutical | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
QCOR Questcor Pharmaceutical

An SI Board Since June 2011

Posts	SubjectMarks	Bans	Symbol
107	13	0	QCOR

Emcee: Savant	Type: Moderated

Introduction Market Data Compact

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary product helps patients with serious, difficult-to-treat medical conditions. Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications. Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of acute exacerbations of multiple sclerosis in adults, the treatment of nephrotic syndrome, and the treatment of infantile spasms in children under two years of age. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus." Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need. Questcor also markets Doral(R) (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit www.questcor.com.

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
107	Mallinckrodt Boosts Guidance as Loss NarrowsBy Michael Calia	Savant	-	8/7/2014
106	Questcor Enters Into Development Collaboration Agreement Covering No	Savant	-	5/14/2014
105	Mallinckrodt Pharmaceuticals and Questcor Pharmaceuticals Announce E	Savant	-	5/12/2014
104	Questcor Pharma 1Q Adj EPS $1.40 >QCORQuestcor Reports Fir	Savant	-	4/28/2014
103	Questcor to Report First Quarter Financial Results on April 28, 2014	Savant	-	4/24/2014
102	Mallinckrodt to Buy Questcor for $5.6 Billion -- UpdateBy Jonathan	Savant	-	4/7/2014
101	Divvies... a tax on shorts...	sense	-	1/28/2014
100	This prolly helped the Jan pps increase..Questcor Pharmaceuticals, Inc. (	Savant	-	1/28/2014
99	They've been dramatically short this thing since below $4... Which mostly s	sense	-	1/28/2014
98	Questcor Pharma rebounds from after-hours lows, but still -3% on com	Savant	-	12/19/2013
97	fwiw, QCOR bounced up from 200 Day SMA, which also filled the gap up from July 3	Savant	-	12/13/2013
96	Questcor Announces Quarterly Cash Dividend and Provides Update on Share	Savant	-	12/11/2013
95	Questcor Honored as an "Everyday Hero" by NephCure Foundat	Savant	-	11/27/2013
94	Questcor Reports Third Quarter Financial ResultsQuestcor Repo	Savant	-	10/30/2013
93	Questcor To Commence Phase 2 Study of Acthar for Acute Respiratory D	Savant	-	10/22/2013
92	Questcor Pharmaceuticals Inc. (QCOR) increased its quarterly divid	Savant	-	10/17/2013
91	Questcor 2nd-Quarter Net Up 67% on Increased Acthar Adoption By Kristin Jones Q	Savant	-	7/31/2013
90	Questcor to Commence Phase 2 Study of Acthar for ALS ANAHEIM, Calif., July 24, 2	Savant	-	7/25/2013
89	Questcor to Report Second Quarter Financial Results on July 30, 2013 ANAHEIM,	Savant	-	7/12/2013
88	Questcor to Initiate Pilot Commercialization Effort In Pulmonology for Symptomat	Savant	-	7/11/2013
87	So much for the "threat" of competitors making synthetics... "U	sense	-	6/26/2013
86	fwiw; i am fully out now. this last bit was a wonderful surprise.	mopgcw	-	6/12/2013
85	Questcor Pharmaceuticals Acquires Rights to Synacthen(R) - Expands Questcor'	Savant	-	6/11/2013
84	UnitedHealth (UNH) Now Covering Questcor's (QCOR) Acthar	mopgcw	-	6/7/2013
83	Questcor Pharmaceuticals Announces Quarterly Dividend ANAHEIM, Calif., May 29	Savant	-	5/29/2013

Go to reply# or date (mm/dd/yy):